WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406719

CAS#: 934358-00-6

Description: TBCA, also known as tetrabromocinnamic acid, is a potent CK2 inhibitor. TBCA inhibits CK2 five times more efficiently than TBB (IC50 values 0.11 and 0.56 microM, respectively), without having any comparable effect on DYRK1 a (IC50 24.5 microM) or on a panel of 28 protein kinases. The usefulness of TBCA for cellular studies has been validated by showing that it reduces the viability of Jurkat cells more efficiently than TBB through enhancement of apoptosis.

Chemical Structure

CAS# 934358-00-6

Theoretical Analysis

MedKoo Cat#: 406719
Name: TBCA
CAS#: 934358-00-6
Chemical Formula: C9H4Br4O2
Exact Mass: 459.69448
Molecular Weight: 463.74286
Elemental Analysis: C, 23.31; H, 0.87; Br, 68.92; O, 6.90

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: TBCA, tetrabromocinnamic acid

IUPAC/Chemical Name: (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid


InChi Code: InChI=1S/C9H4Br4O2/c10-5-3-4(1-2-6(14)15)7(11)9(13)8(5)12/h1-3H,(H,14,15)/b2-1+

SMILES Code: O=C(O)/C=C/C1=CC(Br)=C(Br)C(Br)=C1Br

Appearance: White solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 463.74286 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Lee HR, Shin HK, Park SY, Kim HY, Lee WS, Rhim BY, Hong KW, Kim CD. Attenuation of β-amyloid-induced tauopathy via activation of CK2α/SIRT1: Targeting for cilostazol. J Neurosci Res. 2014 Feb;92(2):206-17. doi: 10.1002/jnr.23310. Epub 2013 Nov 19. PubMed PMID: 24254769.

2: Ryu SY, Kim S. Evaluation of CK2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA) in regulation of platelet function. Eur J Pharmacol. 2013 Nov 15;720(1-3):391-400. doi: 10.1016/j.ejphar.2013.09.064. Epub 2013 Oct 15. PubMed PMID: 24140231.

3: Lee HR, Park SY, Kim HY, Shin HK, Lee WS, Rhim BY, Hong KW, Kim CD. Protection by cilostazol against amyloid-β(1-40)-induced suppression of viability and neurite elongation through activation of CK2α in HT22 mouse hippocampal cells. J Neurosci Res. 2012 Aug;90(8):1566-76. doi: 10.1002/jnr.23037. Epub 2012 Mar 16. PubMed PMID: 22422579.

4: Yao K, Youn H, Gao X, Huang B, Zhou F, Li B, Han H. Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells. Prostate. 2012 Sep 15;72(13):1423-30. doi: 10.1002/pros.22493. Epub 2012 Jan 30. PubMed PMID: 22290244.

5: Kim GS, Jung JE, Narasimhan P, Sakata H, Yoshioka H, Song YS, Okami N, Chan PH. Release of mitochondrial apoptogenic factors and cell death are mediated by CK2 and NADPH oxidase. J Cereb Blood Flow Metab. 2012 Apr;32(4):720-30. doi: 10.1038/jcbfm.2011.176. Epub 2011 Dec 7. PubMed PMID: 22146192; PubMed Central PMCID: PMC3318149.

6: Kramerov AA, Golub AG, Bdzhola VG, Yarmoluk SM, Ahmed K, Bretner M, Ljubimov AV. Treatment of cultured human astrocytes and vascular endothelial cells with protein kinase CK2 inhibitors induces early changes in cell shape and cytoskeleton. Mol Cell Biochem. 2011 Mar;349(1-2):125-37. doi: 10.1007/s11010-010-0667-3. Epub 2010 Dec 2. PubMed PMID: 21125314; PubMed Central PMCID: PMC3426611.

7: Pagano MA, Poletto G, Di Maira G, Cozza G, Ruzzene M, Sarno S, Bain J, Elliott M, Moro S, Zagotto G, Meggio F, Pinna LA. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007 Jan 2;8(1):129-39. PubMed PMID: 17133643.